Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Bergamo – page 2

388 clinical trials in Bergamo, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bergamo at a glance
388
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

388 trials in Bergamo

Open in trial search

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BeOne Medicines I GmbH

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bergamo

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials exploring treatments for heart failure prevention and cardiovascular disease. Studies include evaluation of novel drug combinations and therapies for patients with elevated cardiovascular risks.

  • Heart Failure Prevention
  • Myocardial Infarction Treatment
  • Cardiovascular Risk Management
02 Oncology Studies

Comprehensive research focusing on various cancer types, including non-small cell lung cancer and prostate cancer. Studies evaluate innovative treatment approaches combining immunotherapy with traditional methods.

  • Lung Cancer Therapies
  • Prostate Cancer Treatment
  • Breast Cancer Research
03 Rare Diseases

Specialized trials investigating treatments for conditions like Alagille syndrome and amyotrophic lateral sclerosis. Research focuses on improving patient outcomes and quality of life.

  • Genetic Disorders
  • Neurological Conditions
  • Rare Blood Disorders
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.